Clinical Trials
13 trialsNCT05036226 2026-05-13
COAST
Medical University of South Carolina
Phase 1/2 Recruiting
NCT01480154 2026-04-13
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06408298 2026-02-04
HCQ in Resectable Localized Prostate Cancer
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Recruiting
NCT04011410 2025-04-11
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
University of Kentucky
Phase 2 Completed
NCT03513211 2023-11-22
HITMAN-PC
St Vincent's Hospital, Sydney
Phase 1/2 Completed
NCT00786682 2023-08-14
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT00726596 2022-06-16
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT02765594 2017-09-20
HCQIgAN
Peking Union Medical College Hospital
Phase 4 Unknown
NCT01828476 2017-05-04
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT02421575 2017-02-02
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Terminated
NCT01144169 2016-10-26
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma
University of Pittsburgh
Phase 1 Terminated